The impact of disease-modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis: a retrospective cross-sectional study.

ABSTRACT:

Background

Although disease-modifying therapies (DMTs) in multiple sclerosis (MS) are known to target the immune system, mechanisms of action, efficacy, safety, and tolerability profiles differ. The long-term impact of DMTs on the immune system and its relation to infectious complications is still poorly understood.

Objectives

To analyze the effect of DMTs on serum immunoglobulin (Ig) levels under consideration of patient demographics and therapy duration.

Design

We included 483 patients on DMTs, 69 patients without DMTs, and 51 controls in this retrospective cross-sectional study.

Methods

IgG, IgM, and IgG subclass 1-4 levels of patients with MS under treatment with DMTs were compared with treatment naive MS patients and controls by multivariate linear regress

SUBMITTER: Klein A 

PROVIDER: S-EPMC10126592 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature